Neurobiological Technologies (Neurobiological Technologies) Change In Working Capital : $-24.19 Mil (TTM As of Sep. 2009)

View and export this data going back to 1994. Start your Free Trial

What is Neurobiological Technologies Change In Working Capital?

Neurobiological Technologies's change in working capital for the quarter that ended in Sep. 2009 was $-2.91 Mil.

Neurobiological Technologies's change in working capital for the fiscal year that ended in Jun. 2009 was $-21.62 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Neurobiological Technologies Change In Working Capital Historical Data

The historical data trend for Neurobiological Technologies's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurobiological Technologies Change In Working Capital Chart

Neurobiological Technologies Annual Data

Trend

Jun00

Jun01

Jun02

Jun03

Jun04

Jun05

Jun06

Jun07

Jun08

Jun09

Change In Working Capital

Get a 7-Day Free Trial

2.82

24.30

0.77

-6.32

-21.62

Neurobiological Technologies Quarterly Data
	Dec04	Mar05	Jun05	Sep05	Dec05	Mar06	Jun06	Sep06	Dec06	Mar07	Jun07	Sep07	Dec07	Mar08	Jun08	Sep08	Dec08	Mar09	Jun09	Sep09
Change In Working Capital	Get a 7-Day Free Trial															-0.34	2.45	-3.38	-20.35	-2.91

Neurobiological Technologies Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Sep. 2009 adds up the quarterly data reported by the company within the most recent 12 months, which was $-24.19 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Neurobiological Technologies Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Neurobiological Technologies's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Neurobiological Technologies (Neurobiological Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neurobiological Technologies Inc (OTCPK:NTII) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

2010 Crow Canyon Place, Suite 100, San Ramon, CA, USA, 94583

Website

http://www.ntii.com

Neurobiological Technologies Inc is a biopharmaceutical company historically focused on developing investigational drugs for central nervous system conditions.

Executives

Ariel Warszawski	10 percent owner	C/O FIREFLY VALUE PARTNERS, LP, 551 FIFTH AVENUE, 36TH FLOOR, NEW YORK NY 10176
Ryan Heslop	10 percent owner	C/O FIREFLY VALUE PARTNERS, LP, 551 FIFTH AVENUE, 36TH FLOOR, NEW YORK NY 10176
Firefly Management Co Gp, Llc	10 percent owner	C/O FIREFLY VALUE PARTNERS, LP, 551 FIFTH AVENUE, 36TH FLOOR, NEW YORK NY 10176
Fvp Gp, Llc	10 percent owner	C/O FIREFLY VALUE PARTNERS, LP, 551 FIFTH AVENUE, 36TH FLOOR, NEW YORK NY 10176
Firefly Value Partners, Lp	10 percent owner	426 PINEVILLE ROAD, UNIT 1, NEWTOWN PA 18940
Fvp Master Fund Lp	10 percent owner	FVP GP LLC, 551 FIFTH AVENUE, 36TH FLOOR, New York NY 10176
John B Stuppin	director
Abraham E Cohen	director	500 SEVENTH AVE 10TH FL, C/O AXONYX INC, NEW YORK NY 10018
Abraham D Sofaer	director	HOOVER INSTITUTION, STANFORD UNIVERSITY, STANFORD CA 94305-6010
Biotechnology Value Fund L P	other: Direct Beneficial Owner	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Partners L P/il	10 percent owner	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Inc/il	10 percent owner	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp	other: Direct Beneficial Owner	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Investments Llc	other: Direct Beneficial Owner	1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Mark N Lampert	10 percent owner	1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104

Neurobiological Technologies (Neurobiological Technologies) Headlines

From GuruFocus

Neurobiological Technologies Inc. Reports Operating Results (10-Q)

By gurufocus • 05-09-2009

Neurobiological Technologies Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 02-12-2010

Neurobiological Technologies Inc. Reports Operating Results (10-Q)

By gurufocus • 02-12-2009

Neurobiological Technologies Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 11-16-2009